R. Scott Greer
Director/Board Member bei NEKTAR THERAPEUTICS
Vermögen: 283 538 $ am 31.03.2024
Profil
R.
Scott Greer, as managing director of Numenor Ventures, LLC, is a private investor in and consultant to the life sciences industry with over 30 years experience.
Mr. Greer has made direct investments in over 25 healthcare, technology, and consumer product companies.
He was a founder of Abgenix, Inc., a publicly traded biotechnology company focused on developing and commercializing human antibody based therapeutics, serving as its Chief Executive Officer from its inception in 1996 through 2002 and as its Chairman of the Board from 2000 until 2006.
Mr. Greer was an investor in and Chairman of the Board of Sirna Therapeutics.
He was a director of and investor in Auspex Pharmaceuticals.
Prior to forming Abgenix, Mr. Greer spent five years at Cell Genesys, Inc., a publicly traded biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development through its early development and initial public offering, and later as Senior Vice President of Corporate Development.
Mr. Greer also held various positions at Genetics Institute, Inc.
Mr. Greer is currently a director of several public biopharmaceutical and medical device companies including: Nektar Therapeutics (Nasdaq: NKTR), StemCells, Inc. (Nasdaq: STEM), Versartis, Inc (Nasdaq: VSAR), Inogen, Inc. (Nasdaq: INGN), and Sientra, Inc. (Nasdaq: SIEN).
He is also Chairman of the Board of Calimmune, Inc. In the past he was a director of Illumina, Inc. (Nasdaq: ILMN), CV Therapeutics, Inc. (Nasdaq: CVTX), Affymax, Inc. (Nasdaq: AFFY), Auspex, Inc. (Nasdaq: ASPX), BAROnova, Inc., Chimeros, Inc., and Anaptys BioScience, Inc. He also served as Chairman of the Board of Inogen, Inc. and Ablexis, Inc.
Mr. Greer has a B.A.
in economics from Whitman College and an M.B.A.
from Harvard University.
Mr. Greer served on the board of the Santa Barbara Maritime Museum from 2003-2006.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NEKTAR THERAPEUTICS
0,17% | 19.09.2023 | 303 574 ( 0,17% ) | 283 538 $ | 31.03.2024 |
Aktive Positionen von R. Scott Greer
| Unternehmen | Position | Beginn |
|---|---|---|
| NEKTAR THERAPEUTICS | Director/Board Member | 01.01.2010 |
Numenor Ventures LLC
 Numenor Ventures LLC Investment ManagersFinance Numenor Ventures LLC (Numenor Ventures) is a venture capital firm founded in 2004 by R. Scott Greer. The firm is headquartered in Santa Barbara, California. | Founder | 01.01.2002 |
Ehemalige bekannte Positionen von R. Scott Greer
| Unternehmen | Position | Ende |
|---|---|---|
| INOGEN, INC. | Director/Board Member | 24.05.2021 |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Director/Board Member | 12.10.2018 |
| SIENTRA, INC. | Director/Board Member | 01.07.2018 |
| ARAVIVE, INC. | Director/Board Member | 31.12.2017 |
Calimmune, Inc.
 Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | Chairman | 31.08.2017 |
Ausbildung von R. Scott Greer
| Whitman College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| ILLUMINA, INC. | Health Technology |
| INOGEN, INC. | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| AFFYMAX, INC. | Health Technology |
| SIENTRA, INC. | Health Technology |
| ARAVIVE, INC. | Health Technology |
| Private Unternehmen | 14 |
|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
StemCells, Inc.
 StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Abgenix, Inc.
 Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
BAROnova, Inc.
 BAROnova, Inc. Medical DistributorsDistribution Services BAROnova, Inc. operates as a clinical-stage medical-device company. It develops nonsurgical, nonpharmacologic devices. The firm's TransPyloric Shuttle device enables the patient' stomach to fill up faster, stay full longer, and potentially delay gastric emptying. The company was founded by Hugh Narciso in 2006 and is headquartered in Goleta, CA. | Distribution Services |
Acologix, Inc.
 Acologix, Inc. Pharmaceuticals: MajorHealth Technology Acologix, Inc. develops and commercializes medicines. The company was founded by Yoshinari Kumagai in 1992 and is headquartered in Hayward, CA. | Health Technology |
Numenor Ventures LLC
Numenor Ventures LLC Investment ManagersFinance Numenor Ventures LLC (Numenor Ventures) is a venture capital firm founded in 2004 by R. Scott Greer. The firm is headquartered in Santa Barbara, California. | Finance |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA. | Health Technology |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Calimmune, Inc.
Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | Health Technology |
| Auspex, Inc. | |
Ablexis LLC
 Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Technology Services |
